Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain

Sickle Cell Patient’s AML Likely Unrelated To LentiGlobin

 
• By Alaric DeArment
Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
An analyses by bluebird bio probably rules out its gene therapy as the culprit behind a patient in its SCD study developing acute myeloid leukemia • Source: Shutterstock

More from R&D

More from Scrip